Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Journal for Immunotherapy of Cancer
Lucie HeinzerlingJason J Luke

Abstract

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essentia...Continue Reading

Associated Clinical Trials

References

Aug 8, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Julie A LucasVicki R Kelley
Jul 10, 2009·The New England Journal of Medicine·Fouad FadelBertrand Knebelmann
Aug 5, 2009·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Gary HunterChristopher A Robinson
Apr 23, 2010·International Immunology·Jian WangTaku Okazaki
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Mar 2, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Wilgenhof, B Neyns
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Sep 21, 2011·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Grazia GrazianiPierluigi Navarra
Nov 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wouter V VogelChristian U Blank
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter A PrietoGiao Q Phan
Apr 12, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Margarite L TarrioAndrew H Lichtman
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caroline VoskensLucie Heinzerling
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Apr 4, 2014·Science Translational Medicine·Shintaro IwamaPatrizio Caturegli
Nov 22, 2014·Journal of Immunotherapy·Matthew M K ChanNicholas Manolios
Feb 24, 2015·Journal for Immunotherapy of Cancer·Benjamin P GeislerDavid R Schwartz
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 23, 2015·Journal for Immunotherapy of Cancer·Heinz LäubliAlfred Zippelius
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Apr 17, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lisa ZimmerLucie M Heinzerling
Apr 18, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lars HofmannLucie M Heinzerling

❮ Previous
Next ❯

Citations

Oct 16, 2016·Expert Opinion on Drug Safety·Egle RamelyteReinhard Dummer
Feb 28, 2017·Cancer·Douglas B JohnsonAlexander M Menzies
Apr 4, 2017·British Journal of Pharmacology·A C Foks, J Kuiper
Apr 13, 2017·Current Treatment Options in Cardiovascular Medicine·Varun JainAna Barac
Apr 12, 2017·Antioxidants & Redox Signaling·Carlo Gabriele TocchettiGiuseppe Mercuro
Jun 9, 2017·PloS One·Marta SpodziejaSylwia Rodziewicz-Motowidło
May 5, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A ChauhanL Anthony
Jul 15, 2017·The British Journal of Radiology·William H McBrideDörthe Schaue
Jul 7, 2017·Expert Opinion on Drug Safety·Aine O'Reilly, James Larkin
Dec 8, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kathryn W JuchemWarren D Shlomchik
Oct 27, 2017·Case Reports in Oncology·Yoko FukasawaNobuhiko Seki
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
Mar 24, 2018·Current Oncology Reports·Masutaka FurueHiroshi Uchi
Mar 22, 2018·Expert Review of Anticancer Therapy·Pol Specenier
Aug 24, 2017·Journal of Forensic Sciences·Daniel R MatsonRobert F Corliss
Feb 24, 2018·Frontiers in Cardiovascular Medicine·Jerry Dong, Hong Chen
Nov 22, 2017·Journal for Immunotherapy of Cancer·Timothy G NorwoodRobert M Conry
Nov 23, 2017·Journal for Immunotherapy of Cancer·I PuzanovUNKNOWN Society for Immunotherapy of Cancer Toxicity Management Working Group
Oct 28, 2017·Journal of Immunotherapy·Azadeh Tajmir-RiahiLucie Heinzerling
Jun 26, 2018·Current Heart Failure Reports·Zarina Sharalaya, Patrick Collier
Aug 2, 2018·Current Oncology Reports·David J Palmieri, Matteo S Carlino
Aug 4, 2018·Der Nervenarzt·S KnaussM Endres
Feb 21, 2018·Journal of Immunotherapy·Daniel V P de AlmeidaAntonio C Buzaid
Aug 22, 2018·Expert Opinion on Drug Safety·Antonis A ManolisAntonis S Manolis
Aug 15, 2018·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Ouidad ZehouCéleste Lebbé
Aug 12, 2017·Circulation. Arrhythmia and Electrophysiology·Vitaly BuzaAnne B Curtis
Nov 7, 2017·ESMO Open·Gilda VarricchiCarlo Gabriele Tocchetti
Jan 26, 2018·BMJ Case Reports·Faisal InayatWaqas Ullah
Dec 24, 2018·Expert Review of Anticancer Therapy·Barouyr BaroudjianUNKNOWN PATIO group
Jun 19, 2018·Cardiology in Review·Aaron D BrumbaughWilliam H Frishman
Feb 5, 2019·Cardiovascular Research·Jiun-Ruey HuJavid Moslehi
Mar 14, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·John A ThompsonJillian L Scavone
Mar 30, 2019·Current Opinion in Cardiology·Jayant Raikhelkar, Nir Uriel
Feb 16, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Yazeed SamaraConstantin A Dasanu
Mar 10, 2019·Toxicological Sciences : an Official Journal of the Society of Toxicology·James L WeaverKristina E Howard
Apr 28, 2019·Journal of Cancer Research and Clinical Oncology·Suheil Albert Atallah-YunesJaime Hernandez-Montfort
May 16, 2018·Experimental Hematology & Oncology·Shagufta ShaheenChung-Tsen Hsueh
Jun 9, 2019·Current Treatment Options in Cardiovascular Medicine·Lili ZhangTomas G Neilan
Aug 7, 2019·Expert Opinion on Biological Therapy·Ryan M McCormack, Balveen Kaur

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Clinical Trials Mentioned

NCT01927419

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.